Paz-Ares, LSpira, ARaben, DPlanchard, DCho, B CÖzgüroğlu, MDaniel, DVillegas, AVicente, DHui, RMurakami, SSpigel, DSenan, SLanger, C JPerez, B ABoothman, A-MBroadhurst, HWadsworth, CDennis, P AAntonia, S JFaivre-Finn, C2023-02-082023-02-082020-03-21http://hdl.handle.net/10668/15280In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%, PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TCenPACIFICPD-L1 expressiondurvalumabimmunotherapynon-small-cell lung cancerstage IIIAntibodies, MonoclonalB7-H1 AntigenCarcinoma, Non-Small-Cell LungHumansLung Neoplasmsresearch article32209338open access10.1016/j.annonc.2020.03.2871569-8041PMC8412232http://www.annalsofoncology.org/article/S0923753420363742/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412232/pdf